API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Fexinidazole Winthrop is reffered to as the first oral treatment of acute form of sleeping sickness (rhodesiense) which is found in East and Southern Africa.
Lead Product(s): Fexinidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Fexinidazole Winthrop
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
The US Food and Drug Administration has approved fexinidazole as the first alloral treatment for both stages of the Trypanosoma brucei gambiense form of sleeping sickness (Human African trypanosomiasis) in patients 6 years of age and older and weighing at least 20 kg.
Lead Product(s): Fexinidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2021
Details:
A new five-year US$ 25 million (US$ 5 million/year) financial support to prevent and treat Neglected Tropical Diseases. The development of the first oral drug, fexinidazole, in partnership with DNDi, has simplified the treatment of patients in the most remote areas.
Lead Product(s): Fexinidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 15, 2020